Oryzon Genomics to Present at the 18th Annual BIO CEO & Investor Conference 2016


Oryzon Genomics (ISIN Code: ES0167733015), a clinical stage biopharmaceutical company leveraging epigenetics to develop therapies in oncology and neurodegenerative diseases, announced today that Dr. Carlos Buesa, Oryzon’s Chief Executive Officer, is scheduled to present at the 2016 BIO CEO & Investor Conference being held February 8-9, 2016 at the Waldorf Astoria Hotel in New York City.

Dr. Buesa’s presentation will take place on Monday, February 8th 2016 at 1 pm EST in the Louis XVI room during the conference's Oncology Track.

Click here to see the full Press Release